

NOTICE: For the convenience of capital market participants, Chugai makes efforts to provide English translations of the information disclosed in Japanese, provided that the Japanese original prevails over its English translation in the case of any discrepancy found between documentation.



CHUGAI PHARMACEUTICAL CO., LTD.

A member of the Roche group

CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited)
(for the first quarter of the fiscal year 2018)

Name of Company: Chugai Pharmaceutical Co., Ltd. April 24, 2018
 Stock Listing: Tokyo Stock Exchange
 Security Code No.: 4519 (URL <https://www.chugai-pharm.co.jp/english>)
 Representative: Tatsuro Kosaka, Representative Director, President
 Contact: Masahiko Uchida, General Manager of Corporate Communications Department
 Phone: +81-(0)3-3273-0881
 Date of Submission of Quarterly Marketable Securities Filings: April 27, 2018
 Date on which Dividend Payments to Commence: —
 Supplementary Materials Prepared for the Quarterly Financial Statements: Yes
 Presentation Held to Explain the Quarterly Financial Statements: Yes (for institutional investors and securities analysts)

(Note: Amounts of less than one million yen are rounded.)

1. Consolidated results for the first quarter of FY 2018 (January 1, 2018–March 31, 2018)

(1) Consolidated operating results

	Revenues	% change	Operating profit	% change	Net income	% change
First three months of FY 2018	¥147,427 million	17.5	¥38,362 million	45.6	¥28,153 million	50.3
First three months of FY 2017	¥125,467 million	4.6	¥26,345 million	31.4	¥18,725 million	27.4

	Net income attributable to Chugai shareholders	% change	Total comprehensive income	% change
First three months of FY 2018	¥27,888 million	50.7	¥25,613 million	65.6
First three months of FY 2017	¥18,500 million	27.6	¥15,467 million	52.9

	Earnings per share (Basic)	Earnings per share (Diluted)
First three months of FY 2018	¥51.00	¥50.91
First three months of FY 2017	¥33.86	¥33.81

Note: Percentages represent changes compared with the same period of the previous fiscal year.

(2) Consolidated results (balance sheet)

	Total assets	Total equity	Equity attributable to Chugai shareholders	Ratio of equity attributable to Chugai shareholders
As of Mar. 31, 2018	¥852,886 million	¥711,344 million	¥710,133 million	83.3%
As of Dec. 31, 2017	¥852,473 million	¥692,897 million	¥691,924 million	81.2%

2. Dividends

	Annual dividends per share				
	End of first quarter	End of second quarter	End of third quarter	End of fiscal year	Total
FY ended Dec. 2017	—	¥29.00	—	¥33.00	¥62.00
FY ending Dec. 2018	—				
FY ending Dec. 2018 (Forecast)		¥31.00	—	¥31.00	¥62.00

Note: Whether the most recent dividend forecast has been revised: No

3. Consolidated forecasts for FY 2018 (January 1, 2018–December 31, 2018)

	Revenues	% change	Core operating profit	% change	Core earnings per share		Core dividend payout ratio %
	First three months of FY 2018 (Results)	¥147,427 million	27.2	¥42,804 million	39.6	¥56.52	38.4
FY ending Dec. 2018 (Forecast)	¥541,500 million	1.4	¥108,000 million	4.7	¥147.00	6.0	42.2

Notes: 1. Percentages shown for forecasts of revenues, Core operating profit and Core EPS represent changes from the same period of the previous fiscal year. Percentages for results represent the percentage of forecast levels that have been achieved to date.

2. Whether the most recent forecasts for consolidated figures have been revised: No

3. The figures for the consolidated forecasts and actuals are calculated based on Core basis indicators established by Chugai Pharmaceutical Co., Ltd. ("Chugai") and used on a consistent basis. Core EPS is diluted earnings per share attributable to Chugai shareholders on a Core basis.

4. Others

(1) Changes in the state of material subsidiaries during the period (Changes in the state of specific subsidiaries with change in scope of consolidation): None

(2) Changes in accounting policies and changes in accounting estimates

(a) Changes in accounting policies required by IFRS: Yes

(b) Changes in accounting policies other than those in (a) above: None

(c) Changes in accounting estimates: None

(3) Number of shares issued (common stock):

(a) Number of shares issued at the end of the period (including treasury stock)

As of Mar. 31, 2018	559,685,889	As of Dec. 31, 2017	559,685,889
As of Mar. 31, 2018	12,812,738	As of Dec. 31, 2017	12,909,947
First three months of FY 2018	546,811,132	First three months of FY 2017	546,315,436

(b) Number of treasury stock at the end of the period

(c) Average number of shares issued during the period (three months)

Notes:

The quarterly financial statements are not subject to quarterly reviews.

Explanation of the appropriate use of performance forecasts and other related items

(1) Portions of this report that refer to performance forecasts or any other future events are believed to be reasonable under information available at the time of the forecasts. Actual results may differ from these forecasts due to potential risks and uncertainties.

(2) The forecast which is published for shareholders and investors is based on the internal management indicator Core basis under International Financial Reporting Standards ("IFRS"). The difference between IFRS results and Core results will be explained at each event and presentation.

(3) For the specifics of the forecasts, please refer to "Forecast for consolidated performance" on page 5 of the attached document.

(4) Chugai is scheduled to hold a conference call for investors as noted below. The materials used for the call, the verbal recording, the Q&A, and other related documents will be posted on the Chugai's website following the conclusion of the conference call. Teleconference for institutional investors and securities analysts (Japanese only): April 24, 2018, Tuesday (Japan time). The English translation of the conference materials will be posted on the website on the next business day.

Index of the Attachment

1. Qualitative Information	2
(1) Consolidated operating results	2
(2) Consolidated financial position	4
(3) Forecast for consolidated performance	5
2. Interim Condensed Consolidated Financial Statements and Major Notes	6
(1) Interim condensed consolidated income statement and interim condensed consolidated statement of comprehensive income	6
(2) Interim condensed consolidated balance sheet	8
(3) Interim condensed consolidated statement of cash flows	9
(4) Interim condensed consolidated statement of changes in equity	10
(5) Notes regarding the going concern assumption	11
(6) Notes regarding the interim condensed consolidated financial statements	11

1. Qualitative Information

(1) Consolidated operating results in billions of yen

	First three months of FY 2018.12 (Jan. 1, 2018–Mar. 31, 2018)	First three months of FY 2017.12 (Jan. 1, 2017–Mar. 31, 2017)	% change
Core results			
Revenues	147.4	125.5	+17.5
Sales (excluding Tamiflu)	116.3	110.8	+5.0
Tamiflu sales	8.4	7.4	+13.5
Royalties and other operating income	22.7	7.3	+211.0
Cost of sales	(63.5)	(60.9)	+4.3
Gross profit	83.9	64.6	+29.9
Marketing and distribution	(15.9)	(15.4)	+3.2
Research and development	(20.9)	(19.2)	+8.9
General and administration	(4.3)	(3.3)	+30.3
Operating profit	42.8	26.7	+60.3
Net income	31.2	18.9	+65.1
IFRS results			
Revenues	147.4	125.5	+17.5
Operating profit	38.4	26.3	+46.0
Net income	28.2	18.7	+50.8

Consolidated financial highlights (IFRS results)

Revenues for the three months under review were ¥147.4 billion (an increase of 17.5% year on year), operating profit for the three months under review was ¥38.4 billion (an increase of 46.0% year on year), and net income for the three months under review was ¥28.2 billion (an increase of 50.8% year on year). These results include non-Core items, such as amortization of intangible assets of ¥0.4 billion and impairment loss of intangible assets of ¥4.1 billion, which are excluded from the Core results that Chugai adopts to manage recurring business activities.

Consolidated financial highlights (Core results)

Revenues for the three months under review were ¥147.4 billion (an increase of 17.5% year on year), due to increases in sales and royalties and other operating income.

Of revenues, sales excluding Tamiflu were ¥116.3 billion (an increase of 5.0% year on year), mainly due to increases in Actemra and other exports to Roche. Royalties and other operating income amounted to ¥22.7 billion (an increase of 211.0% year on year), due to an increase of one-time income and others resulting from the transfer of long-term listed products to Taiyo Pharma Co., Ltd, etc.

Cost to sales ratio was 50.9%, a 0.7 percentage point improvement year on year, due to the effect of exchange rates, etc. As a result, gross profit amounted to ¥83.9 billion (an increase of 29.9% year on year).

Operating expenses were ¥41.1 billion (an increase of 8.4% year on year). Marketing and distribution expenses were ¥15.9 billion (an increase of 3.2% year on year) due to the effect of exchange rates, etc., research and development expenses amounted to ¥20.9 billion (an increase of 8.9% year on year) due to the progress of projects, and general and administration expenses amounted to ¥4.3 billion (an increase of 30.3% year on year) due to an increase in various expenses including the enterprise tax (pro forma standard taxation). As a result, Core operating profit was ¥42.8 billion (an increase of 60.3% year on year) and Core net income was ¥31.2 billion (an increase of 65.1% year on year).

Note: Core results

Chugai discloses its results on a Core basis from 2013 in conjunction with its transition to IFRS. Core results are the results after adjusting non-recurring items recognized by Chugai to IFRS results, and are consistent with the Core concept disclosed by Roche. Core results are used by Chugai as an internal performance indicator, for explaining the status of recurring profits both internally and externally, and as the basis for payment-by-results.

For further details regarding the adjustment to IFRS results, please refer to the Supplementary Materials on page 5, entitled "Reconciliation of IFRS results to Core results."

Sales breakdown in billions of yen

	First three months of FY 2018.12 (Jan. 1, 2018–Mar. 31, 2018)	First three months of FY 2017.12 (Jan. 1, 2017–Mar. 31, 2017)	% change
Sales	124.7	118.1	+5.6
Domestic sales (excluding Tamiflu)	84.5	85.1	(0.7)
Oncology	48.6	49.3	(1.4)
Bone and joint diseases	21.6	20.4	+5.9
Renal diseases	8.0	8.3	(3.6)
Others	6.2	7.1	(12.7)
Tamiflu sales	8.4	7.4	+13.5
Ordinary use	8.3	6.1	+36.1
Government stockpiles	0.1	1.3	(92.3)
Overseas sales	31.9	25.6	+24.6

Domestic sales (excluding Tamiflu)

Domestic sales excluding Tamiflu were ¥84.5 billion (a decrease of 0.7% year on year) due to a decrease in sales of some products, despite steady growth of Alecensa (an ALK inhibitor, anti-cancer agent), as well as mainstay products in the bone and joint diseases area.

Oncology products sales were ¥48.6 billion (a decrease of 1.4% year on year). This decrease was due to a decrease in sales of Herceptin (an anti-HER2 humanized monoclonal antibody, anti-cancer agent) and Rituxan (an anti-CD20 monoclonal antibody, anti-cancer agent), despite favorable performance of Alecensa (an ALK inhibitor, anti-cancer agent) and Perjeta (an HER2 dimerization inhibitory humanized monoclonal antibody, anti-cancer agent).

Bone and joint diseases products sales were ¥21.6 billion (an increase of 5.9% year on year). This was due to the robust sales of mainstay products such as Actemra (a humanized anti-IL-6 receptor monoclonal antibody), Ediol (an oral therapeutic agent for osteoporosis), and Bonviva (a bisphosphonate for osteoporosis).

Renal diseases products sales amounted to ¥8.0 billion (a decrease of 3.6% year on year) due to a decline in sales of some products, despite maintenance in sales of Oxarol (an agent for secondary hyperparathyroidism) and Mircera (a long-acting erythropoiesis-stimulating agent) at the same level as the previous year.

Others products sales were ¥6.2 billion (a decrease of 12.7% year on year) due to a decrease in sales of Rohypnol, whose marketing authorization was transferred in the previous year and others.

Tamiflu sales

Sales of Tamiflu (an anti-influenza agent) for ordinary use were ¥8.3 billion (an increase of 36.1% year on year), while sales to government stockpiles etc. were ¥0.1 billion (a decrease of 92.3% year on year).

Overseas sales

Overseas sales amounted to ¥31.9 billion (an increase of 24.6% year on year) due mainly to increases in exports of Actemra and Hemlibra to Roche.

(2) Consolidated financial position**Assets, liabilities, and net assets** in billions of yen

	March 31, 2018	December 31, 2017	% change
Movements of assets and liabilities			
Net working capital	231.8	250.7	(7.5)
Long-term net operating assets	205.7	189.5	+8.5
Net operating assets (NOA)	437.5	440.2	(0.6)
Net cash	266.3	242.8	+9.7
Other non-operating assets – net	7.6	9.9	(23.2)
Total net assets	711.3	692.9	+2.7
Consolidated balance sheet (IFRS basis)			
Total assets	852.9	852.5	+0.0
Total liabilities	(141.5)	(159.6)	(11.3)
Total net assets	711.3	692.9	+2.7

Net working capital at March 31, 2018 was ¥231.8 billion (a decrease of ¥18.9 billion since December 31, 2017). This was because the sum of the decrease in accounts receivable-trade and the increase in accounts payable-trade outweighed the sum of the decrease in accounts payable-other. Long-term net operating assets increased by ¥16.2 billion since the end of the previous fiscal year to ¥205.7 billion, due mainly to an increase in property, plant and equipment. As a result, net operating assets (NOA) were ¥437.5 billion, a decrease of ¥2.7 billion from the end of the previous fiscal year.

As the table entitled “Cash flows” on the next page indicates, net cash, including marketable securities and interest-bearing debt, increased by ¥23.5 billion since December 31, 2017 to ¥266.3 billion. Other non-operating assets - net decreased by ¥2.3 billion from the end of the previous fiscal year to ¥7.6 billion, due mainly to a decrease in investment securities.

With the application of IFRS 15 ‘Revenue from Contracts with Customers,’ deferred income of ¥10.6 billion after tax effect, which was included in net working capital and long-term net operating assets at the beginning of the year, has been presented as retained earnings.

As a consequence, total net assets were ¥711.3 billion (an increase of ¥18.4 billion since December 31, 2017).

Note: Movements of assets and liabilities

The consolidated balance sheet has been prepared in accordance with International Accounting Standards (IAS) No. 1, “Presentation of Financial Statements.” On the other hand, “Movements of assets and liabilities” including net operating assets (NOA) are a reconfiguration of the consolidated balance sheet as internal indicators and are identical to the indicators disclosed by Roche. Furthermore, no items from the assets and liabilities have been excluded, as the Core results concept only applies to the income statement.

For further details, please refer to the Supplementary Materials on page 8, entitled “Movements of assets and liabilities.”

Note: Net operating assets (NOA)

Net operating assets allow for an assessment of the Group’s operating performance of the business independently from financing and tax activities. Net operating assets are calculated as net working capital, long-term net operating assets that includes property, plant and equipment, intangible assets etc. minus provisions.

Cash flows in billions of yen

	First three months of FY 2018.12 (Jan. 1, 2018–Mar. 31, 2018)	First three months of FY 2017.12 (Jan. 1, 2017–Mar. 31, 2017)	% change
Movements of free cash flows			
Operating profit - IFRS basis	38.4	26.3	+46.0
Operating profit, net of operating cash adjustments	47.1	30.8	+52.9
Operating free cash flows	56.3	33.6	+67.6
Free cash flows	42.3	21.4	+97.7
Net change in net cash	23.5	6.5	+261.5
Consolidated statement of cash flows (IFRS basis)			
Cash flows from operating activities	50.8	30.7	+65.5
Cash flows from investing activities	(18.5)	(7.8)	+137.2
Cash flows from financing activities	(17.8)	(14.2)	+25.4
Net change in cash and cash equivalents	13.7	8.3	+65.1
Cash and cash equivalents at March 31	152.8	103.7	+47.3

Operating profit, net of operating cash adjustments, amounted to ¥47.1 billion. This is calculated by adjusting for depreciation and other items that are included in operating profit but are not accompanied by cash inflows or outflows and all inflows and outflows related to NOA that are not accompanied by profit and loss. The principal items influencing this result were a total of ¥4.1 billion in impairment loss of intangible assets.

Operating free cash flows, which are calculated by adding a decrease in net working capital of ¥20.5 billion and also subtracting expenditures of ¥11.3 billion for the purchase of property, plant and equipment and intangible assets from operating profit, net of operating cash adjustments, amounted to a net inflow of ¥56.3 billion. Factors accounting for the decrease in net working capital are as shown on the previous page in the table entitled “Assets, liabilities, and net assets.” Purchases of property, plant and equipment were mainly expenditures for purchase of buildings and equipment of the laboratories and plants.

Free cash flows were a net cash inflow of ¥42.3 billion. This is calculated by subtracting a total of ¥14.0 billion of non-operating cash outflows from financial asset management, settlement for transfer pricing taxation and income taxes paid from operating free cash flows.

The net change in net cash, after dividends paid and foreign currency translation adjustments, was an increase of ¥23.5 billion in comparison with the end of the previous fiscal year. The net change in cash and cash equivalents, excluding changes in marketable securities and interest-bearing debt, was a net cash inflow of ¥13.7 billion. The cash and cash equivalents balance at the end of the first quarter amounted to ¥152.8 billion.

Note: Movements of free cash flows (FCF)

The consolidated statement of cash flows has been prepared in accordance with International Accounting Standard (IAS) No. 7, “Statement of Cash Flows.” FCF is a reconfiguration of the consolidated statement of cash flows as internal indicators and is identical to the indicators disclosed by Roche. Furthermore, no items from FCF have been excluded, as the Core results concept only applies to the income statement.

For further details, please refer to the Supplementary Materials on page 9, entitled “Movements of free cash flows.”

(3) Forecast for consolidated performance

Chugai has not made any changes in its forecast of consolidated results for the fiscal year ending December 31, 2018 since the announcement regarding the forecast issued on February 1, 2018.

Note: In “1. Qualitative Information,” amounts less than ¥0.1 billion have been rounded to the nearest ¥0.1 billion. Figures for changes in amounts and percentages have been calculated using data denominated in ¥0.1 billion units.

2. Interim Condensed Consolidated Financial Statements and Major Notes

(1) Interim condensed consolidated income statement and interim condensed consolidated statement of comprehensive income

1) Interim condensed consolidated income statement in millions of yen

	First three months ended March 31	
	2018	2017
Revenues	147,427	125,467
Sales	124,744	118,149
Royalties and other operating income	22,683	7,318
Cost of sales	(63,829)	(61,167)
Gross profit	83,598	64,300
Marketing and distribution	(15,887)	(15,425)
Research and development	(25,052)	(19,255)
General and administration	(4,297)	(3,275)
Operating profit	38,362	26,345
Financing costs	(42)	(43)
Other financial income (expense)	(64)	(268)
Other expense	(602)	(1,079)
Profit before taxes	37,653	24,955
Income taxes	(9,500)	(6,229)
Net income	28,153	18,725
Attributable to:		
Chugai shareholders	27,888	18,500
Non-controlling interests	266	225
Earnings per share		
Basic (yen)	51.00	33.86
Diluted (yen)	50.91	33.81

2) Interim condensed consolidated statement of comprehensive income in millions of yen

	First three months ended March 31	
	2018	2017
Net income recognized in income statement	28,153	18,725
Other comprehensive income		
Fair value changes on equity investments at fair value through OCI	(184)	—
Items that will never be reclassified to the income statement	(184)	—
Available-for-sale investments	—	(58)
Fair value changes on debt investments at fair value through OCI	0	—
Cash flow hedges	(1,160)	(2,241)
Currency translation of foreign operations	(1,197)	(959)
Items that are or may be reclassified to the income statement	(2,357)	(3,259)
Other comprehensive income, net of tax	(2,540)	(3,259)
Total comprehensive income	25,613	15,467
Attributable to:		
Chugai shareholders	25,375	15,263
Non-controlling interests	238	204

(2) Interim condensed consolidated balance sheet in millions of yen

	March 31, 2018	December 31, 2017
Assets		
Non-current assets:		
Property, plant and equipment	174,648	171,569
Intangible assets	17,853	21,078
Financial non-current assets	8,213	11,350
Deferred tax assets	31,277	34,501
Other non-current assets	16,635	14,836
Total non-current assets	248,627	253,333
Current assets:		
Inventories	168,097	169,056
Accounts receivable	154,051	174,284
Current income tax assets	33	717
Marketable securities	113,803	104,018
Cash and cash equivalents	152,819	139,074
Other current assets	15,457	11,990
Total current assets	604,260	599,141
Total assets	852,886	852,473
Liabilities		
Non-current liabilities:		
Long-term debt	(180)	(207)
Deferred tax liabilities	(8,453)	(9,211)
Defined benefit plan liabilities	(9,568)	(9,292)
Long-term provisions	(2,037)	(2,041)
Other non-current liabilities	(1,446)	(15,923)
Total non-current liabilities	(21,684)	(36,674)
Current liabilities:		
Short-term debt	(134)	(129)
Current income tax liabilities	(12,212)	(18,541)
Short-term provisions	(26)	(79)
Accounts payable	(66,925)	(63,518)
Other current liabilities	(40,560)	(40,635)
Total current liabilities	(119,858)	(122,902)
Total liabilities	(141,542)	(159,576)
Total net assets	711,344	692,897
Equity:		
Capital and reserves attributable to Chugai shareholders	710,133	691,924
Equity attributable to non-controlling interests	1,211	973
Total equity	711,344	692,897

(3) Interim condensed consolidated statement of cash flows in millions of yen

	First three months ended March 31	
	2018	2017
Cash flows from operating activities		
Cash generated from operations	48,199	31,796
(Increase) decrease in working capital	20,476	12,201
Payments made for defined benefit plans	(783)	(717)
Utilization of provisions	(3)	—
Other operating cash flows	(319)	(1,645)
Cash flows from operating activities, before income taxes paid	67,571	41,635
Income taxes paid	(16,766)	(10,902)
Total cash flows from operating activities	50,805	30,733
Cash flows from investing activities		
Purchase of property, plant and equipment	(9,891)	(5,315)
Purchase of intangible assets	(1,426)	(4,025)
Disposal of property, plant and equipment	(41)	13
Interest and dividends received	13	38
Purchases of marketable securities	(66,000)	(56,011)
Sales of marketable securities	56,022	57,500
Sales of investment securities	2,863	—
Other investing cash flows	(2)	(2)
Total cash flows from investing activities	(18,462)	(7,802)
Cash flows from financing activities		
Interest paid	(1)	(2)
Dividends paid to Chugai shareholders	(17,941)	(14,089)
Dividends paid to non-controlling shareholders	—	(360)
Exercise of equity compensation plans	174	316
(Increase) decrease in own equity instruments	(4)	(1)
Other financing cash flows	(61)	(75)
Total cash flows from financing activities	(17,833)	(14,211)
Net effect of currency translation on cash and cash equivalents	(765)	(431)
Increase (decrease) in cash and cash equivalents	13,745	8,289
Cash and cash equivalents at January 1	139,074	95,368
Cash and cash equivalents at March 31	152,819	103,658

(4) Interim condensed consolidated statement of changes in equity in millions of yen**For the first three months ended March 31, 2017 (Jan. 1, 2017 – Mar. 31, 2017)**

	Attributable to Chugai shareholders					Non-controlling interests	Total equity
	Share capital	Capital surplus	Retained earnings	Other reserves	Subtotal		
At January 1, 2017	72,967	63,500	507,399	1,642	645,508	989	646,497
Net income	—	—	18,500	—	18,500	225	18,725
Available-for-sale investments	—	—	—	(58)	(58)	—	(58)
Cash flow hedges	—	—	—	(2,241)	(2,241)	—	(2,241)
Currency translation of foreign operations	—	—	—	(938)	(938)	(21)	(959)
Total comprehensive income	—	—	18,500	(3,238)	15,263	204	15,467
Dividends	—	—	(14,203)	—	(14,203)	(360)	(14,563)
Equity compensation plans	—	11	—	—	11	—	11
Own equity instruments	—	419	—	—	419	—	419
At March 31, 2017	72,967	63,929	511,696	(1,595)	646,997	833	647,830

For the first three months ended March 31, 2018 (Jan. 1, 2018 – Mar. 31, 2018)

	Attributable to Chugai shareholders					Non-controlling interests	Total equity
	Share capital	Capital surplus	Retained earnings	Other reserves	Subtotal		
At January 1, 2018	72,970	64,815	550,974	3,166	691,924	973	692,897
Impact of changes in accounting policies	—	—	10,606	—	10,606	—	10,606
At January 1, 2018 (revised)	72,970	64,815	561,580	3,166	702,530	973	703,503
Net income	—	—	27,888	—	27,888	266	28,153
Net change in fair value – financial assets at fair value through OCI	—	—	—	(184)	(184)	—	(184)
Cash flow hedges	—	—	—	(1,160)	(1,160)	—	(1,160)
Currency translation of foreign operations	—	—	—	(1,169)	(1,169)	(27)	(1,197)
Total comprehensive income	—	—	27,888	(2,513)	25,375	238	25,613
Dividends	—	—	(18,044)	—	(18,044)	—	(18,044)
Equity compensation plans	23	(20)	—	—	3	—	3
Own equity instruments	—	268	—	—	268	—	268
Transfer from other reserves to retained earnings	—	—	1,498	(1,498)	—	—	—
At March 31, 2018	72,992	65,063	572,922	(844)	710,133	1,211	711,344

(5) Notes regarding the going concern assumption

None

(6) Notes regarding the interim condensed consolidated financial statements**1) General accounting principles and significant accounting policies****a. Basis of preparation of the consolidated financial statements**

These financial statements are the interim condensed consolidated financial statements (“Interim Financial Statements”) of Chugai, a company registered in Japan, and its subsidiaries (“the Group”). The common stock of Chugai is publicly traded and listed on the Tokyo Stock Exchange under the stock code “TSE: 4519.” The Interim Financial Statements were approved by the Board of Directors on April 24, 2018.

Roche Holding Ltd. is a public company registered in Switzerland and the parent company of the Roche Group, which discloses its results in accordance with IFRS. The shareholding percentage of Roche Holding Ltd. in Chugai is 59.89% (61.29% of the total number of shares issued excluding treasury stock). The Group became principal members of the Roche Group after entering into a strategic alliance in October 2002.

The Group meets all of the requirements for a “Specified Company under Designated International Financial Reporting Standards” as stipulated under Article 1-2 of the “Ordinance on Terminology, Forms, and Preparation Methods of Quarterly Consolidated Financial Statements” (Japanese Cabinet Ordinance No. 64, 2007). Hence, in accordance with Article 93 of the same Ordinance, the Interim Financial Statements have been prepared in accordance with International Accounting Standard (IAS) No. 34 “Interim Financial Reporting.”

The Interim Financial Statements should be used with the consolidated financial statements for the year ended December 31, 2017 as they do not include all the information as required for the consolidated financial statements for the full fiscal year.

The Interim Financial Statements are presented in Japanese yen, which is Chugai’s functional currency and amounts are rounded to the nearest ¥1 million. They have been prepared using the historical cost convention except for items that are required to be accounted for at fair value.

b. Key accounting judgments, estimates and assumptions

The preparation of the Interim Financial Statements requires management to make judgments, estimates, and assumptions that affect the reported amounts of revenues, expenses, assets, liabilities, and contingent amounts. Actual outcomes could differ from those management estimates. The estimates and underlying assumptions are reviewed on an on-going basis and are based on historical experience and various other factors. Revisions to estimates are recognized in the period in which the estimate is revised.

The information for judgment, estimates, and assumptions that have a material impact on the amount recognized in the Interim Financial Statements of the Group is principally the same for the prior fiscal year.

c. Significant accounting policies

The Group applies the same significant accounting policies that are used for the previous fiscal year to the Interim Financial Statements, except for those stated in d. Changes in accounting policies below.

d. Changes in accounting policies

In 2018 the Group implemented the following new standards, including any consequential amendments to other standards, with a date of initial application of 1 January 2018.

- IFRS 9 ‘Financial Instruments’
- IFRS 15 ‘Revenue from Contracts with Customers’

The nature and the effects of the changes most relevant to the Group's Interim Financial Statements are given below.

IFRS 9 'Financial Instruments'

Effective 1 January 2018 the Group has implemented IFRS 9 'Financial Instruments'. The new standard replaces IAS 39 'Financial Instruments: Recognition and Measurement'. The standard deals with the classification, recognition and measurement (including impairment) of financial instruments and also introduces a new hedge accounting model.

There is no material impact on the Group's performance or financial position from the application of this standard.

Classification and measurement of financial instruments.

Items such as equity securities and debt securities which were previously classified as available-for-sale under IAS 39, with the exception of time accounts over three months, are classified as financial assets at fair value through other comprehensive income (OCI), and time accounts over three months as amortised cost. Though the Group takes advantage of the exemption allowing it not to restate comparative information for prior periods with respect to classification and measurement changes, since there were no changes in the carrying amounts, no adjustments were made to retained earnings as of January 1, 2018.

Changes in the fair value of equity instruments designated as financial assets at fair value through other comprehensive income are recognized in other comprehensive income, and the cumulative amount of other comprehensive income is transferred to retained earnings when the instruments are derecognized.

Impairment of financial assets.

On 1 January 2018 the Group changed the methodology of assessing impairment of its financial assets from the incurred loss model (used in IAS 39) to the expected credit loss model (used in IFRS 9). In accordance with the transitional provisions of IFRS 9, the Group has not restated prior periods but it has reassessed the impairment allowances under the new approach as of 1 January 2018. As the impact of the transition was immaterial, the Group has recognized it as profit and loss for the fiscal year.

Hedge accounting.

As the Group may continue to apply the hedge accounting requirements of IAS 39 instead of those in IFRS 9 at the initial application of IFRS 9, the Group has chosen to continue to apply the hedge accounting requirements of IAS 39.

IFRS 15 ‘Revenue from Contracts with Customers’

Effective 1 January 2018 the Group has implemented IFRS 15 ‘Revenue from contracts with customers’. The new standard replaces IAS 18 ‘Revenue’ and IAS 11 ‘Construction Contracts’. IFRS 15 establishes a comprehensive framework for determining whether, how much and when revenue is recognised, and also contains new requirements related to presentation. The core principle in that framework is that revenue should be recognised dependent on the transfer of promised goods or services to the customer for an amount that reflects the consideration which should be received in exchange for those goods or services. The objective of the standard is to provide a five-step approach to revenue recognition that includes identifying contracts with customers, identifying performance obligations, determining transaction prices, allocating transaction prices to performance obligations, and recognising revenue when or as performance obligations are satisfied. Judgement will need to be applied, including making estimates and assumptions, for multiple-element contracts in identifying performance obligations, in constraining estimates of variable consideration and in allocating the transaction price to each performance obligation. The new standard results in an increased volume of disclosure information in the Annual Financial Statements.

Changes introduced by the standard relevant to the Group.

The new standard provides new requirements and additional guidance that are relevant to the Group, notably on the following areas:

- Revenues from licenses of intellectual property, including sales-based royalties, on constraining estimates of variable consideration such as e.g. development milestones that may be regarded as a separate performance obligation involving variable consideration. There is no material impact from these changes.
- The new standard also clarifies how to allocate sales, including the treatment of discounts, to each element in multiple-elements contracts and when to recognise sales for each of those elements. It requires the use of estimates and assumptions and some judgement to apply this guidance in practice. There is no material impact from this guidance.
- Out-licensing contracts may be entered into with no further obligation or may include commitments to research, late-stage development, regulatory approval, co-marketing or manufacturing. These may be settled by a combination of up-front payments, milestone payments, and reimbursements for services provided. Whether to consider these commitments as a single performance obligation or separate ones, or even being in scope of IFRS 15, is not straight-forward and requires some judgement. Depending on the conclusion, this may result in all revenue being calculated at inception and either being recognised at once or spread over the term of a longer performance obligation. With the application of this standard, upfront payment received, which was formerly recognized over time as deferred income, is recognized as one-time income on out-licensing.

Transition approach.

The Group recognizes the cumulative effect of applying the new standard at the date of initial application, with no restatement of the comparative periods presented. It records the cumulative effect, the amount of ¥10,606 million after tax effect, as an adjustment to the opening balance of retained earnings at the date of initial application. Except for this adjustment, there is no material impact on the Group’s performance or financial position from the application of this standard.